{"entity":{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","aka":[],"tldr":"Heron Therapeutics makes long-acting supportive-care injectables: the antiemetics Sustol (extended-release granisetron) and Cinvanti (aprepitant emulsion), plus the post-surgical analgesic Zynrelef.","summary":"Heron Therapeutics, based in Cary, North Carolina, and listed as HRTX, makes long-acting supportive care injectables: the antiemetics Sustol, an extended-release granisetron, and Cinvanti, an aprepitant emulsion, plus the post-surgical analgesic Zynrelef. Its polymer-based extended-release technology underlies Sustol, approved in 2016 for chemotherapy-induced nausea and vomiting, and Cinvanti, an intravenous aprepitant approved in 2017, while Aponvie and Zynrelef serve the surgical market. OnCo links it to the aprepitant and granisetron drug records. Whether long-acting formulations of generic antiemetics can command a premium is the commercial question its oncology products face. Granisetron and aprepitant have their own pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.herontx.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["granisetron","aprepitant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cary, North Carolina","country":"US","companyType":"biotech","website":"https://www.herontx.com","ticker":"HRTX","investors":[],"funding":[]},"route":"/companies/heron-therapeutics/","neighbours":{"drug":[{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/"},{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/"}],"trial":[{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/"}]}}